Ronald D. Guttmann, MD, FRCPC, Vice President, Clinical Development
Dr. Guttmann is Emeritus Professor of Medicine and former Director of the McGill University Centre for Clinical Immunobiology and Transplantation. Dr. Guttmann has been active in the biomedical industry and biotechnology investment consulting since 1985.
Richard J. Albertini, MD, PhD, Vice President of Research
Dr. Albertini is Emeritus Professor of Medicine at the University of Vermont, former Director of the Vermont Cancer Center. He served as President of the Environmental Mutagen Society from 1983-84. Dr. Albertini received the Alexander Hollaender Award of the Environmental Mutagen Society in 1990 and the St. George Medal of the American Cancer Society that same year.
Ronald D. Guttmann, (see above)
Mark Allegretta, PhD, Dr. Allegretta has over 20 years of experience in biotechnology and academic research and development. He received his PhD from the University of Vermont in 1990, and was a post-doctoral fellow at Stanford University School of Medicine. Dr. Allegretta is a co-founder of EndoGen and was most recently associated with Connetics Corporation and InterMune Pharmaceuticals. He is currently Associate Vice President of Commercial Research for the National Multiple Sclerosis Society.
Thomas S. Gillespie, B.C.L. Mr. Gillespie is the former President of Tyringham Investments and prior to 2001 he was a Senior Partner of Ogilvy Renault, a major Canadian law firm, where he was a member of the firm’s Executive Committee for ten years. Mr. Gillespie has served as a director or officer of a number of corporations including Volvo Canada, Guerlin Canada, Imperial Tobacco of Canada, and the Daily Mail and General Trust, England.
Our products and technology are developed through collaboration. These valuable connections enable BioMosaics to continue providing cutting edge products and service in the oncology diagnostics market. Our Glypican-3 antibody products were invented by Professor Jorge Filmus PhD, Department of Medical Biophysics, Sunnybrook Health Sciences Centre. Also, we are currently working with the Molecular Imaging Program and the Asian Liver Center at Stanford University for development of our GPC3 antibody-based PET imaging diagnostic test. For more information about our collaborators, visit our Partnerships page.